Lila Sciences raised $235 million in Series A funding to scale its AI-driven scientific discovery platform that integrates generative AI, robotics, and automated lab systems. The company aims to accelerate drug development timelines by conducting autonomous experiments and analytical processes with minimal human intervention. The substantial capital infusion supports expansion of research talent and global operations, positioning Lila as a leader in AI-powered life sciences innovation to tackle major human health challenges.